This dual anti-inflammatory and antioxidant action contributes to the neuroprotective effects of SGLT-2 inhibitors, potentially slowing the progression of cognitive decline and neurodegenerative processes in patients with diabetes. Here, SLC5A2 is linked to diabetes mellitus.